**Chinese Medical Team Releases Dual-Target CAR-T Data: 100% Complete Remission Rate in High-Risk MM Patients**

**Chinese Medical Team Releases Dual-Target CAR-T Data: 100% Complete Remission Rate in High-Risk MM Patients**

High-Risk MM

#CARTTherapy #MultipleMyeloma #BCMA #CD19 #JAMAOncology #MM #HRMM #DualTarget

Once again, a Chinese medical team is at the forefront of innovation, making significant strides in the field of CAR-T cell therapy. A recent study published in *JAMA Oncology* (B-Cell Maturation Antigen/CD19 Dual-Targeting Immunotherapy in Newly Diagnosed Multiple Myeloma) revealed remarkable results for the dual-target BCMA/CD19 CAR-T therapy in high-risk newly diagnosed multiple myeloma (NDMM) patients. In this study, all 19 participants achieved stringent complete remission (sCR) and were found to be minimal residual disease (MRD) negative, resulting in an astounding 100% remission rate.

**CAR-T Therapy: A Breakthrough in Hematologic Cancer Treatment**

Multiple myeloma (MM) is a challenging hematologic cancer, particularly for patients with high-risk features, where traditional treatments often show limited efficacy. CAR-T cell therapy is an innovative immunotherapy that reprograms a patient’s own T cells to recognize and attack cancer cells. In recent years, this therapy has shown significant success in treating leukemia, lymphoma, and relapsed/refractory MM (RRMM). The latest study further demonstrates that dual-target CAR-T therapy, focusing on BCMA and CD19, can significantly improve the prognosis for high-risk MM patients.

**The Impressive Results of China’s Dual-Target CAR-T Therapy**

The CAR-T therapy used in this study, GC012F, targets both B-cell maturation antigen (BCMA) and CD19 surface antigens, showing powerful anti-tumor effects. Every patient in the study not only achieved complete remission after treatment but also maintained a long-term MRD-negative status, meaning that traces of cancer cells were nearly undetectable post-therapy.

More importantly, the study highlighted the swift effectiveness of the Chinese GC012F therapy—patients reached their first complete remission in a median time of just 84 days, with MRD-negative status achieved in as little as 28 days. This rapid anti-tumor response provides a crucial treatment window for patients, significantly improving their prognosis.

**Safety and Future Prospects**

In addition to its impressive efficacy, GC012F demonstrated favorable safety. Only 27% of patients experienced mild to moderate cytokine release syndrome (CRS), and no cases of immune effector cell-associated neurotoxicity syndrome (ICANS) were observed. This is in stark contrast to previous studies in relapsed/refractory patients, where CRS rates were higher, highlighting the safety advantage of this therapy in newly diagnosed patients.

Though the study sample size was small, these findings bring new hope for high-risk multiple myeloma patients. As larger clinical trials are conducted and combination therapies are explored, this therapy has the potential to offer better survival outcomes for more patients.

**Conclusion**

China’s CAR-T cell therapy research continues to lead the way in hematologic cancer treatment. The success of the BCMA/CD19 dual-target CAR-T therapy not only demonstrates its strong efficacy in high-risk multiple myeloma but also provides a new direction for treating hematologic cancers globally. As research deepens, we anticipate that this groundbreaking therapy will bring new life-saving opportunities to more patients.

This breakthrough in Chinese CAR-T therapy represents not only scientific progress but also underscores China’s pivotal role in the global fight against cancer.

To assess whether the condition is suitable for CAR-T therapy, you can submit pathology reports, treatment history, and discharge summaries to the Medical Department of <Advanced Medicine in China> for preliminary evaluation!

WhatsApp: Https://wa.me/+8613717959070

Email: doctor.huang@globecancer.com

#CancerTreatment #Immunotherapy #MedicalInnovation #CancerResearch #ChinaHealthcare #HematologicCancer #CancerBreakthrough

Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78

Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79

2 months ago Myeloma

Groundbreaking Results for Chinese CAR-T Therapy: 86% Response Rate of BCMA/GPRC5D Dual-Target Treatment Multiple myeloma

**Groundbreaking Results for Chinese CAR-T Therapy: 86% Response Rate of BCMA/GPRC5D Dual-Target Treatment**

Multiple myeloma

#MultipleMyeloma #ChineseCART #BCMA #GPRC5D #DualTarget #MM #RRMM

Multiple myeloma (MM) is a challenging blood cancer, particularly in relapsed/refractory (R/R) cases. While therapies like proteasome inhibitors, immunomodulators, CD38 monoclonal antibodies, and stem cell transplants have improved outcomes for newly diagnosed patients, treatment-resistant forms of MM remain a serious concern. A new therapeutic approach combining two targets, BCMA and GPRC5D, may provide a breakthrough solution.

BCMA has long been a key target for treating R/R MM due to its expression in malignant plasma cells. However, BCMA-targeted therapies face limitations, including tumor cells losing or downregulating BCMA, leading to disease recurrence. This is where GPRC5D, a protein highly expressed in MM cells and linked to poor prognosis, comes in. By targeting both BCMA and GPRC5D, researchers aim to overcome the limitations of single-target therapies.

A collaboration between a leading Chinese hospital and research institutions has now delivered promising results. A Phase I clinical trial involving 21 patients with R/R MM using the dual-target BCMA/GPRC5D CAR-T cell therapy reported an overall response rate (ORR) of 86%, with 75% of patients achieving a complete response (CR). Notably, even patients whose cancer cells lacked BCMA or GPRC5D expression showed significant improvement, underscoring the versatility of this treatment.

**Key Results from the Study:**

– 21 patients with advanced, heavily pre-treated R/R MM participated.

– Of the 12 patients who received the optimal dosage of 2.0×10⁶ CAR-T cells/kg, 86% showed clinical response, with 75% achieving complete remission.

– Importantly, patients with BCMA or GPRC5D-negative cancer cells also responded well to treatment.

– The treatment was well-tolerated, with manageable side effects, including 71% of patients experiencing mild to moderate cytokine release syndrome (CRS).

This trial, published in *The Lancet Haematology*, represents a major step forward in MM treatment. The dual-target approach addresses the limitations of BCMA-targeted therapies, offering new hope to patients who have exhausted conventional options.

Looking ahead, this innovative therapy could reshape the future of multiple myeloma treatment, offering a powerful new tool in the fight against this complex disease.

🎉🎉To assess whether the condition is suitable for CAR-T or clinic therapy, you can submit Advanced Medicine in China for preliminary evaluation!
WhatsApp: +8613717959070
Email: doctor.huang@globecancer.com

#CancerResearch #MultipleMyeloma #CAR_TTherapy #MedicalInnovation #OncologyBreakthrough